Frost & Sullivan has awarded Stratum Nutrition the 2018 North American Competitive Strategy Innovation and Leadership Award for the Joint Health Ingredient Industry for Stratum’s NEM brand eggshell membrane ingredient.
Photo © iStockphoto.com/adventtr
Frost & Sullivan has awarded Stratum Nutrition the 2018 North American Competitive Strategy Innovation and Leadership Award for the Joint Health Ingredient Industry for Stratum’s NEM brand eggshell membrane ingredient.
“Stratum Nutrition’s NEM offers highly effective and fast-acting joint health benefits supported by strong and growing scientific evidence. Its strategy and approach to vigorously pursue science to back its ingredients’ health benefits are best-in-class and unrivalled by any other competitors,” commented Frost and Sullivan. “Stratum Nutrition’s exceptional competitive strategy and multifaceted innovation approach to product development offers its customers unique opportunities to enhance the value of their own health products. This is altogether unmatched by other competitors and has earned Stratum Nutrition the market-leading position.”
Frost & Sullivan based its decision on several criteria, specifically analyzing two key factors: strategy innovation and customer impact. For strategy innovation, Frost & Sullivan considers the effectiveness and execution of the strategy as well as competitive differentiation, executive team alignment, and stakeholder integration. For customer impact, they consider the price/performance value, the customer’s purchase, ownership and service experience, and brand equity.
“It’s an honor to receive this Frost & Sullivan award,” said director of brand and product strategy at Stratum Nutrition, Andrew Rice, in a press release. “Our team’s passion to help others live healthier lives is the motivation for our unrelenting hunger to provide unique ingredients backed by unparalleled science, quality, and innovation.”
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.